A syndrome akin to graft-versus-host disease in the recipient of syngeneic stem cells is hitherto described as being milder, self-limiting and confined to the skin. It is enhanced by prior cyclosporin A therapy. We describe here a recipient of a syngeneic marrow transplant who did not receive priming with cyclosporin A and yet developed severe and progressive graft-versushost disease which necessitated and responded to highdose immunosuppressive therapy. We believe that this is because the conditioning regimen in stem cell transplant acts to reset the immune system enabling it to recognise 'self' antigens. Bone Marrow Transplantation (2000) 25, 205-207. Keywords: syngeneic; marrow transplant; severe GVHD; immunosuppressive drugs Clinical and histological changes consistent with graftversus-host disease (GVHD) have been described in recipients of both syngeneic and autologous grafts.
Clinical and histological changes consistent with graftversus-host disease (GVHD) have been described in recipients of both syngeneic and autologous grafts. [1] [2] However, this is usually associated with cyclosporin A therapy and is generally mild and self limiting. 3 We present the case of a young boy who received a syngeneic bone marrow transplant (BMT) for acute myeloid leukemia (AML) and subsequently developed severe GVHD necessitating and responding to high-dose immunosuppressive therapy. There had been no prior cyclosporin A therapy.
Case report
A 15-year-old Chinese boy was diagnosed as having acute myeloid leukemia of the M2 subtype. He received standard induction and consolidation therapy comprising idarubicin and cytosine arabinoside followed by a course of high-dose cytosine arabinoside.
He had an identical twin brother with whom DNA variable number tandem repeats (VNTR) were identical at all loci, thus confirming that patient and donor were genotypically as well as phenotypically identical.
A syngeneic bone marrow transplant was performed and he was conditioned with busulphan 4 mg/kg p.o. in divided doses daily for 4 days (total dose 16 mg/kg) and cyclophosphamide 60 mg/kg once daily i.v. for 2 days. G-CSF 10 g/kg/day s.c. (Hoffman-LaRoche, Basel, Switzerland) were given from day 1 post transplant. The patient also received antifungal prophylaxis with fluconazole. He did not receive cyclosporin A or total body irradiation. All blood products received were irradiated and filtered.
On day 14 post transplantation (on the day of engraftment), he developed a severe graft-versus-host syndrome manifesting as: (1) generalised erythematous pruritic rash; (2) severe diarrhoea about four times a day with a volume of approximately 1 to 1.5 l; (3) elevated serum bilirubin 40 mmol/l (rising to a peak of 106 mmol/l) with elevated gamma glutamyl transferase 92 mmol/l (rising to a peak of 339 mmol/l).
CT scan of the abdomen was normal. A liver biopsy was inconclusive but did show some apoptosis of hepatocytes. A skin biopsy was not done as steroid therapy was instituted immediately causing the the rash to disappear.
The patient continued to have a rising bilirubin level which rose to a peak of 106 mmol/l (with gamma glutamyl transferase reaching a peak of 339 mmol/l) despite therapy with methylprednisolone initially at 5 mg/kg/day then at 10 mg/kg/day (Figure 1 ). He was then given i.v. OKT3 at 10 to 15 mg a day for 2 weeks which was then rapidly tailed off. He was also started on oral FK506 to control the GVHD. The hyperbilirubinemia appeared to respond to this therapy and he was discharged well on day 50 post transplant.
Discussion
It is generally believed that there are two essential components necessary for the induction of autologous/syngeneic GVHD: firstly, the inhibition of thymic-dependent clonal deletion of autoreactive T lymphocytes by cyclosporin A; secondly, the elimination of a peripheral regulatory mechanism by the preparative regimen (particularly, total body irradiation). 4 In experimental models and humans, cyclosporin A given in autologous and syngeneic BMT has been shown
Days post BMT to produce a syndrome akin to GVHD. This pseudo-GVHD syndrome is generally described as being mild, confined to the skin, self-limiting and non-life-threatening. 3, 4 However, there have been isolated reports where it is severe and progressive, 5 even occurring some months after transplant. 6 Cyclosporin A inhibits IL-2 production (and several other lymphokines) but does not usually prevent the antigen-specific priming of T cells, such that T cells may be poised to respond as soon as cyclosporin is withdrawn, resulting in accelerated GVHD and allograft rejection. In syngeneic BMT, cyclosporin A cripples immune tolerance. This occurs firstly through the inhibition of the intrathymic deletion of clones with relatively low affinity, but not those with high affinity, to self antigens. Secondly, it also appears to inhibit the action of suppressor T cells which normally maintain an innate form of resistance to autoimmunity. Finally, cyclosporin A has been shown to prevent the development of T cell clonal anergy. 7, 8 That our patient developed severe GVHD is borne out by the classic syndrome of severe diarrhoea, skin rash and hyperbilirubinemia occurring at the same time as engraftment. The response to steroids further supports this fact. However, high doses were necessary to control the liver function abnormalities.
This case illustrates that a syndrome akin to GVHD can occur in syngeneic bone marrow transplants which can be fairly severe, necessitating high-dose therapy for control. Also, this can occur even if no cyclosporin (said to induce thymic modulation) or total body irradiation (said to cause ablation of peripheral tolerance) is given to induce a pseudo-GVHD.
This challenges a criterion for the development of GVHD as put forward by Billingham 9 in 1966, which was that the host must possess important transplantation alloantigens that are lacking in the donor graft, so that the host appears foreign to the graft and is, therefore, capable of stimulating it antigenically.
In the case of autologous or syngeneic GVHD both graft and host are identical and do not possess any alloantigens to stimulate each other immunologically. That this pseudo-GVHD syndrome can occur in this setting prompts us to rethink the mechanism of immunological reactivity post BMT.
As there is an absence of HLA disparity, especially in this recipient of a syngeneic transplant, there must be other mechanisms stimulating the recognition of self antigens and this immunological cascade other than direct cytotoxicity from alloreactive T cells. Damage to host tissues during conditioning results in release of inflammatory cytokines such as tumor necrosis factor ␣ (TNF-␣) and interleukin-1 (IL-1), activating both alloreactive and autoreactive T cells. 10 Factors which may reduce infection and interrupt this cascade such as gut decontamination, use of a sterile environment and administration of i.v. immunoglobulin, all reduce the incidence of GVHD. Delayed infusion of alloreactive T cells until after the cytokine cascade has sub-sided may also prevent GVHD while maintaining a graftversus-leukemia effect. 11 We believe that there are more factors than standard T cell interactions accounting for the graft-versus-host effect post BMT. The release of cytokines during conditioning and ablation of the regulatory components in the thymus and peripheral lymphoid tissue causes the body to 'unlearn' some of the immunological reactivity or tolerance it may have gained. It is this modulation and reversion to immunological naivety that probably also explains the utility of autologous BMT in treatment of autoimmune diseases as well as the potential for stimulating a graft-versus-leukemia effect in autologous BMT.
